Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T25889
(Former ID: TTDR00979)
|
|||||
| Target Name |
Adenylate cyclase (ADCY)
|
|||||
| Synonyms |
Adenylyl cyclase; ATP pyrophosphate-lyase
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Literature-reported target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Heart failure [ICD-11: BD10-BD1Z] | |||||
| 2 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
| Function |
Catalyzes the formation of the second messenger cAMP from ATP. Its transcript is probably degraded by endoribonuclease LS (rnlA), decreasing cAMP levels and the negative regulator Crp- cAMP, which then induces its own transcription again.
Click to Show/Hide
|
|||||
| BioChemical Class |
Phosphorus-oxygen lyase
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
| 1 | Ad5-AC6 | Drug Info | Terminated | Cardiac failure | [2] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | Ad5-AC6 | Drug Info | [1] | |||
| Inhibitor | [+] 9 Inhibitor drugs | + | ||||
| 1 | 2,5-didesoxy-3-ATP | Drug Info | [3] | |||
| 2 | 2-hydroxy-17beta-estradiol | Drug Info | [3] | |||
| 3 | Adenosine-5'-Rp-Alpha-Thio-Triphosphate | Drug Info | [4] | |||
| 4 | DEOXYADENOSINE | Drug Info | [5] | |||
| 5 | N6-CYCLOPENTYLADENOSINE | Drug Info | [6] | |||
| 6 | NSC-270718 | Drug Info | [3] | |||
| 7 | NSC-88915 | Drug Info | [3] | |||
| 8 | [3H]alphabeta-meATP | Drug Info | [7] | |||
| 9 | [3H]cAMP | Drug Info | [7] | |||
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Unanticipated Signaling Events Associated with Cardiac Adenylyl Cyclase Gene Transfer. J Mol Cell Cardiol. 2011 May; 50(5): 751-758. | |||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013170) | |||||
| REF 3 | Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem. 2008 Aug 14;51(15):4456-64. | |||||
| REF 4 | DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. | |||||
| REF 5 | Synthesis of 2',5'-dideoxy-2-fluoroadenosine and 2',5'-dideoxy-2,5'-difluoroadenosine: potent P-site inhibitors of adenylyl cyclase. J Med Chem. 2004 Feb 26;47(5):1207-13. | |||||
| REF 6 | Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors. J Med Chem. 1991 Dec;34(12):3388-90. | |||||
| REF 7 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.